Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Transition from nebulised iloprost therapy to subcutaneous treprostinil Source: Eur Respir J 2004; 24: Suppl. 48, 2s Year: 2004
EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Delivery efficiency of electronic and jet nebulisers aerosolising a colistimethate sodium solution Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Pharmacokinetics of 14 C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Administration of isotonic nebulised magnesium sulphate as an adjuvant to ipratropium bromide in treatment of viral wheezing in children Source: Eur Respir J 2006; 28: Suppl. 50, 265s Year: 2006
Novel omalizumab liquid formulation bioequivalent to lyophilized formulation Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Stating the obvious: intravenous magnesium sulphate should be the first parenteral bronchodilator in paediatric asthma exacerbations unresponsive to first-line therapy Source: Breathe, 17 (4) 210113; 10.1183/20734735.0113-2021 Year: 2021
A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Comparison of magnesium sulfate to normal saline as a vehicle for nebulized salbutamol in children with acute asthma; a clinical trial Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Therapeutic and diagnostic use of highly concentrated sodium chloride solution inhalations in pulmonology Source: Eur Respir J 2006; 28: Suppl. 50, 62s Year: 2006